ANI Pharmaceuticals (NASDAQ:ANIP) has launched Bretylium Tosylate Injection USP, 50 mg/mL, a class III antiarrhythmic medication approved for the treatment of ventricular fibrillation and ventricular arrhythmias such as ventricular tachycardia.
The estimated annual U.S. antiarrhythmic market is ~$915M, based on data from IQVIA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.